Notizie AIOM – anno XVII
Nearly 25 Oncology Practices Achieve ASCO’s QOPI Certification to Date in 2019
April 25, 2019 - The American Society of Clinical Oncology, Inc. (ASCO®) commends the 24 practices that took their standard of care to the next level and achieved Quality Oncology Practice Initiative (QOPI®) Certification in the first quarter of this year. By electing ...Leggi tutto
FDA Approves Pembrolizumab/Axitinib Combo for Frontline RCC
April 22, 2019 - The FDA has approved pembrolizumab in combination with axitinib for the frontline treatment of patients with advanced renal cell carcinoma (RCC). The approval is based on findings from the phase III KEYNOTE-426 trial, which demonstrated that the frontline ...Leggi tutto
FDA launches public education campaign to encourage safe removal of unused opioid pain medicines from homes
April 25, 2019 - The U.S. Food and Drug Administration today announced the launch of a new education campaign to help Americans understand the important role they play in removing and properly disposing of unused prescription opioids from their homes. This new initiative ...Leggi tutto
European Immunization Week 2019: statement by Executive Director Guido Rasi
April 24, 2019 - Vaccine-preventable diseases are making a comeback in Europe. Let’s take the example of measles, a potentially deadly disease. From July 2017 to June 2018 alone, more than 13,000 cases of measles were reported across 29 countries of the European Economic ...Leggi tutto
EMA regrets to learn of the passing of Dr Eric Abadie, former CHMP Chair
April 25, 2019 - It is with great sadness that EMA has learned of the recent death of Dr Eric Abadie, former Chair of EMA's Committee for Medicinal Products for Human Use (CHMP). Dr Abadie was a physician specialised in internal medicine, diabetology and cardiology. He was ...Leggi tutto
EMA recommends withdrawal of marketing authorisation for cancer medicine Olaratumab
April 26, 2019 - EMA has completed its assessment of the results of the ANNOUNCE study and concluded that Lartruvo (olaratumab) with doxorubicin does not prolong the lives of patients with soft tissue cancer more than doxorubicin alone. The Agency is therefore recommending ...Leggi tutto
European Approval Sought for Luspatercept for Anemias
April 26, 2019 - A marketing authorization application has been submitted to the European Medicines Agency for luspatercept for the treatment of adult patients with very low- to intermediate-risk myelodysplastic syndrome (MDS)-associated anemia with ring sideroblasts who ...Leggi tutto